Company Overview

Update
Founded:
1985
Founders:
Lee Hood, Marvin Caruthers
Headquarters:
Thousand Oaks, CA
IPO:
Went Public on Jan 24, 1983
Stock:
NASDAQ:AMGN
Categories:
Biotechnology

Amgen engages in the development of human therapeutic products in supportive of cancer care, inflammation, nephrology and bone diseases.

Description

Update

Amgen Inc. - The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation.

The Group's key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis.

Current Team (21)

Update

Board Members and Advisors (12)

Update

Investments (30)

Update

Acquisitions (6)

Update

Funding Rounds (1) - $175.50M

Update

Offices/Locations (1)

Update
  • HQ

    One Amgen Center Drive

    Thousand Oaks, CA 91320-1799

    USA

Images (2)

Update
  • F4129afa803a47dd30deba939586a065
  • Bd93908fed262cfc4612a92c8bc93f6a